reason report
adopt inflect underway initi op pt
bottom line initi coverag share
outperform rate price target believ
current adopt inflect diabet devic
insulin pump continu glucos monitor believ
specif major driver adopt inflect
recent slim basal iq launch driven higher patient switch
mp anima also ramp new patient add
mdi multipl daili inject user partner best-in-class
cgm op develop differenti pump platform
remot upgrad easy-to-us touch screen well
compani mid-term commit launch one new product per year
believ built ever-widen competit moat
major durabl pump player put
posit continu drive patient switch beyond patient switch
constitut tndm patient add -- tndm ease-of-us
posit basal iq patient experi success manag
diabet also driven acceler adopt among mdi
dynam see sustain forese futur
op pt next month believ share
trade arriv valuat use discount cash flow
dcf compar compani ev/sal analysi dcf arriv
valuat compar compani analysi
arriv valuat rang valuat
appli ev/sal multipl sale
estim assum stabl multipl current level
sale repres premium view
sale estim believ top-tier growth profil
clear pathway profit support valuat ev/sal
rang especi given financi overhang remov
result equiti rais improv free cash flow pictur
medic suppli devic
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
initi coverag share outperform rate
price target believ current adopt inflect diabet devic
insulin pump continu glucos monitor believ specif
major driver adopt inflect recent slim basal iq launch driven
higher patient switch anima also ramp new patient add mdi
multipl daili inject user partner best-in-class cgm develop
differenti pump platform remot upgrad easy-to-us touch screen well
compani mid-term commit launch one new product per year believ
built ever-widen competit moat major durabl pump
player put posit continu drive patient switch beyond patient
switch constitut tndm patient add tndm ease-of-us posit
basal iq patient experi success manag diabet also driven acceler
adopt among mdi dynam see sustain forese futur
long-term view pump market opportun compel target larg grow
under-tr patient popul diabet estim world-wide type
svb leerink estim believ posit within type market drive
market share gain via patient switch also bring new patient onto pump therapi
untap opportun estim insulin-depend type market svb leerink
estim instal base type see
sustain strong double-digit sale grower forese futur even potenti
upsid project compound-annual-growth-rate time-frame
meaning ahead consensu out-year -- ahead ahead
ahead believ much above-street estim
out-year due believ key mispercept among analyst investor
believ insulin pump market growth acceler mid-single-digit previous
sustain double-digit growth see potenti even upsid
modest penetr type margin penetr insulin-depend type
increas adopt driven continu product evolut includ tndm upcom slim
control iq launch
beyond like continu estim upsid share could move even higher driven
upcom control iq dataset releas ada american diabet
associ annual meet june
control iq launch believ could drive yet anoth adopt inflect
continu clinic updates/progress next-gener sport expect launch
eventu phone-control help acceler
new patient add mdi patient potenti even ramp adopt
larg still untap market opportun type
tandem insulin pump system address potenti larg market opportun type
diabet estim world-wide still earli stage adopt
estim type diabet intern base pump
survey link physician survey project ultim penetr type
equat market opportun intern assum
averag revenu per patient per year includ pump cost alloc year suppli
cost per year intern today estim
type patient popul penetr less penetr
ou highlight signific runway growth current level
figur total address market
svb leerink estim censu cdc nation diabet report idf diabet
figur attempt demonstr potenti open-end growth opportun
pump therapi base assumpt around ultim penetr type
intern estim current penetr type patient popul
 intern -- repres pump market today --
could ultim reach penetr ramp base pump survey
provid sens what reflect estim pump penetr current
model penetr type intern
 ouswwtyp patient popul revenu per patient per year type type popul revenu per patient per year insulin-depend type market opportun tandem diabet inc
figur type total address market therapi sensit analysi
public svb leerink estim
double-digit sale growth sustain forese futur near-term
sale de-risk view tangibl upsid opportun
tandem project sustain nearli growth rate next year
driven ramp adopt mdi patient shift pump supplement
tndm abil continu drive patient switch major durabl pump
sale compound-annual-growth-rate support increas penetr highli under-
mention previous expect type penetr ramp
ou mean type patient
intern still administr insulin via mdi physician pump
survey link expect increment ramp point ahead us pump reach ultim
penetr diabet market model project modest increment
ramp point point intern type patient popul
leav signific runway growth forese futur pump therapi ultim
becom standard care dynam believ matter
technolog evolv cgm integr continu advanc toward true
penetr worldwideultim penetr internationallytot address market type diabet million tandem diabet inc
figur project penetr type vs
public svb leerink estim
signific portion near-term revenu highli de-risk
believ sale estim lock exit
impli sale highli de-risk includ pump renew
gener total sale assum retent rate reach
exit today suppli sale total sale
 instal base exit estim ou suppli sale
total sale instal base exit estim
figur sale lock
compani report svb leerink estim
clear tangibl opportun upsid coverag
estim upsid sale estim secur
coverag believ like upcom control iq approval/launch
unitedhealthcar issu may coverag decis went effect juli
design in-network durabl insulin pump provid note
new pump ship fell coverag
largest health insur cover live cover
 popul given key point pushback
need clinic outcom data express seem increas confid
abil get back negoti tabl control iq data
present ada june releas full juli ultim think tandem could
potenti secur coverag earli drive upsid current sale
upsid
figur potenti sale upsid unitedhealth coverag assum variou
clear tangibl opportun upsid control iq price premium share
note could potenti implement price premium control iq
achiev via share cost-sav insur provid fact
success secur price premium see upsid current
sale estim hard say success success
implement strategi believ cost-sav offer control iq like
compel insur could motiv particularli pose cost-sav share
control iq presum patient use less insulin due better manag
high low patient also see time rang lead fewer er visit
near-term fewer costli co-morbid long-term assess potenti upsid
assum control iq could save per patient per year repres total
suppli cost see column variabl figur tandem
share total save payer see row variabl figur
shippmentincrement new add unitedhealthcar sale sale tandem diabet inc
figur control iq premium annual cost-sav share per patient belong
base analysi assumpt correct could bring increment sale
repres nearli current sale estim
instal base updat control iq within one year anticip launch
row variabl figur captur increment per patient
per year share cost save control iq demonstr column
variabl figur
figur increment revenu control iq cost-sav per patient per year
 sale control iq premium one-tim reimburs instal base updat control iq exit iq premium annual cost-sav share per patient belong tandem diabet inc
deep pipelin consist product cycl target one new launch expand
well-posit toward artifici pancrea ace design control iq
fda industri work tirelessli toward develop mani perceiv
ultim gold standard diabet care artifici pancrea believ
leapfrog competit upcom control iq launch accuraci
clinic outcom ease-of-us perspect believ artifici pancrea
significantli improv qualiti life insulin-depend patient futur artifici
pancrea essenti cgm sensor-aug insulin pump three key compon
cgm sensor measur glucos level insulin pump deliv insulin
algorithm determin glucos trend control insulin deliveri
toward goal fda releas guidanc regulatori pathway icgm integr
continu glucos monitor conjunct dxcm approv tandem slim also
receiv altern control enabl ace infus pump design fda
establish special control pave way integr artifici pancrea
significantli reduc regulatori burden product evolut go forward tandem slim
pump basal iq technolog first insulin pump design compat icgm
devic first insulin pump ace design posit well view
out-innov major durabl pump competitor futur upcom
control iq launch believ leapfrog control iq provid autom
correct bolus hybrid closed-loop system use much accur sensor
anticip launch sport
beyond control iq expect launch next-gen pump platform hardwar
perspect sport expect half size current-
gener system mobil phone control sport also control iq
algorithm rest pump bolu button pump protect patient
overli reliant phone discreet profil like attract mdi user
believ sport could improv tndm abil drive acceler new patient add
suffici posit carri compani profit
equiti rais anoth exit
cash cash equival encouragingli significantli improv cash flow profil
sale ramp posit free cash flow season strong
modest cash burn base model estim tandem burn
free cash gener posit free cash flow achiev full-year
free cash flow think current cash posit suffici
carri compani consist profit estim
face larg well-entrench competitor strong brand recognit
within pump market face two well-entrench formid competitor
 intern roch europ
market decad much greater resourc hold strong brand
recognit among clinician patient seen figur estim
hold nearli global pump market follow hold global
share highli differenti patch pump longer roch still
strong presenc intern market share roch
significantli larger salesforc much larger market presenc
compet
given half tndm new add come exist pump switcher rather mdi
patient exposed/vulner competit product cycl
figur market share instal base vs
compani report svb leerink estim
gross margin pathway beyond still bit unclear commit
oper margin long-term pipelin help
guid gross margin gm expect exit
gm approach increment leverag beyond gm tougher come
view pump sale account nearli total sale today revenu
mix shift toward suppli lower gross margin pump -- instal base
grow time impos pressur gross margin profil sport product
design lower cog well potenti increment cost-sav premium
control-iq pipelin could help improv margin
compani report svb leerink estim
next month believ share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi dcf
arriv valuat compar compani analysi arriv
month valuat rang valuat appli ev/sal multipl
sale estim assum stabl multipl current level
sale repres premium view compar higher-growth
current trade sale estim believ
top-tier growth profil clear pathway profit support valuat
ev/sal rang especi given financi overhang remov result
equiti rais improv free cash flow pictur
arriv share price discount cash flow analysi
assum weighted-averag cost capit wacc termin growth rate
believ fairli reason given signific runway growth long term
sensit analysi figur demonstr share price deriv dcf
analysi assum variou wacc termin growth rate
termin growth equiti capm calculationrisk free rate risk equiti structuremarket calcul tandem diabet inc
compani report svb leerink estim
actual amort compens work capit cash use provid oper averag discount pv per valuat averag valu equiti per tandem diabet inc
figur sensit analysi price target deriv discount
compar compani analysi room multipl expans
compar compani valuat analysi suggest valuat rang
share current share trade ev/sal base
sale estim well higher-growth smid-cap med-tech group
averag multipl estim sale given tandem top-tier growth profil
next year sale compound-annual-growth-rate believ valuat ev/sal
rang support tndm top-tier growth profil clear pathway profit
appli ev/sal multipl sale estim arriv
price target base compar group multipl coincid pt deriv
figur smid-cap med-tech compar compani similar growth profil
figur valuat base smid-cap med-tech compar compani
compani report svb leerink estim
risk valuat includ inabl gain market share failur bring sport
market sourc margin improv unclear
trade multipl svb leerink estimateslp multiplespt use smid-cap pt use tandem diabet inc
strong double-digit sale growth profil sustain forese futur
believ tandem deliv compound annual top-lin growth
driven continu adopt pump therapi type diabet potenti upsid
insulin-depend type patient exit estim type
patient adopt pump therapi much lower adopt rate
intern expect penetr type popul ramp
 ou still leav signific runway beyond
 expect tandem reach instal base
-- repres increas market share today -- gross
add gradual ramp per year steadi attrit
rate believ increas awar tandem integr cgm
help spur ramp adopt tandem well posit captur patient
new pump therapi
intern tandem deliv pump guid ou sale
rang estim gross add ramp
inclin think estim reason achiev given strong
demand europ jnj anima exit market
compani report svb leerink estim
break-even ebit profit
expect tandem achiev ebit profit net incom profit
net margin reach improv beyond slim drive
continu adopt lock drive sustain revenu stream grow instal base
believ ramp sale off-set fix variabl cost tie manufactur sale
market initi expect tandem achiev gross margin
improv nearli expect compani rapidli drive
posit oper leverag across board boost improv gross margin given
ramp volum lower sg percent sale potenti posit
tandem achiev net margin still leav room margin
improv reach compani long-term goal
tandem gener free cash flow posit strong season burn
sale ramp margin improv expect posit free cash
achiev full-year free cash flow equiti rais anoth
tandem cash debt exit
suffici carri compani profit
outlook strong adopt sustain double-digit sale growth
model sale y/i intern sale
slightli consensu estim total sale y/i
intern sale vs consensu expect tandem drive
posit margin expans driven gross margin expans approach exit
volum ramp improv leverag disciplin spend
figur show estim vs street
tandem medic devic compani headquart san diego california develop
manufactur insulin deliveri system peopl insulin-depend diabet tandem
market devic brand name slim includ gener slim launch
august flex launch may discontinu end slim
dxcm launch septemb discontinu upon slim launch current
flagship product slim dxcm launch septemb slim
dxcm launch follow fda approv slim devic featur user-
friendli touchscreen well highli differenti softwar updat enabl patient
updat pump remot person comput
financi growthconsensusvarianceestimatesy/i growthconsensusvariancetot good gross gener administr develop averag ep revenu actualnewy/i bp consensu bp newy/i bp consensu bp gross consensu incom statement item includ contributor factset consensu compani report factset consensu visibl alpha svb leerink tandem diabet inc
tandem slim smallest durabl insulin pump market pump
featur remot softwar updat slim basal-iq technolog first insulin pump
receiv approv icgm compat follow fda approv dxcm icgm
design februari slim receiv fda design ace altern
control enabl infus pump think new devic categori could provid compani
flexibl collabor cgm manufactur develop futur aid
slim system consist
durabl pump altern durabl pump also
smallest pump market highli differenti touch screen remot softwar
updat asp pump typic reimburs cycl
year
cartridg dispos insulin reservoir capac
type diabet patient need total unit insulin per kilogram bodi
weight day translat unit vast major patient
cartridg last day payer usual reimburs cartridg per year
infus set connect pump patient bodi needl plastic
tube tandem began replac standard luer-lok connector previous join
infus set cartridg lock connector could reduc time
requir fill tube second amount insulin use process
unit current infus set cartridg sold one-to-on basi
payer usual reimburs cartridg per year
slim dxcm
tandem slim pump basal-iq technolog first insulin pump design
compat icgm devic first insulin pump ace design tndm slim
dxcm sensor compat launch shortli launch basal-iq
integr pump/cgm system low glucos suspend believ allow
compet even effect new patient patient switch
particularli given improv accuraci integr dxcm
insulin cartridg insert
slim
slim insulin basal-iq
basal-iq technolog predict prevent glucos level minut ahead basal-
iq autom insulin algorithm predict low glucos suspend plg system design
suspend insulin low blood glucos predict automat resum insulin deliveri
glucos level begin rise basal-iq technolog secur fda approv june
launch juli in-warranti slim pumper abl upgrad pump via
remot softwar updat home
suspend insulin deliveri
basal-iq demonstr reduc hypoglycemia control-iq data present
ada june
improv time rang hypoglycemia prevent tandem prolog studi
demonstr basal-iq effect reduc time hypoglycemia
control arm rebound effect tandem plan present data control-iq pivot studi
ada american diabet associ june support fda approv
figur clinic outcom basal-iq peer
sensor-aug pumpbasal-iqtim rang glucos time mg/dl prolog studypodd horizon pivot tandem diabet inc
anticip launch slim control iq
control iq tandem second-gener aid autom insulin deliveri system hybrid
closed-loop product autom correct bolus integr slim pump
combin dxcm sensor aid technolog licens typezero tandem
near complet control-iq pivot trial plan present result ada
american diabet associ san francisco june plan submit
regulatori file fda control-iq peopl year old juli
plan submit separ regulatori file pediatr data studi
data avail control-iq launch expect ou launch
next-gener hardwar platform expect half size slim
design peopl seek even greater discret flexibl use insulin
pump anticip sport featur low-cost cartridg on-pump bolu
button recharg batteri aid algorithm importantli sport
touchscreen pump control via mobil app phone
separ control much smaller sport without touchscreen associ lower
cog tandem hasnt decid yet whether offer control affect gross
margin contribut product compani expect sport product launch
diabet expens increasingli preval diseas particularli
accord intern diabet feder peopl world-wide suffer
diabet number expect increas reach
accord center diseas control cdc diabet affect peopl
 repres popul patient
diagnos type diabet ou approxim total
diabet type autoimmun disord usual develop childhood
character lack insulin estim diabet
diagnos type newli diagnos type patient year
outsid estim diagnos type patient type patient
alreadi insulin depend requir either pump multipl daili inject therapi
estim anywher type patient current pump therapi
 rest larg perform multipl daili inject mdi outsid pump
penetr type diabet even lower
insulin-depend type diabet ou type diabet
metabol disord result bodi unabl produc suffici amount insulin
becom insulin resist type diabet caus larg part grow obes epidem
addit age popul also drive growth diabet patient popul
preval diabet increas age reach high among age year
older vs popul age estim diagnos type patient
 today includ insulin-depend type diabet
undiagnos intern estim nearli diagnos type patient includ
insulin-depend type diabet patient undiagnos earli type
diabet forgiv diseas patient avoid treatment due lack signific
symptom poor manag catch patient long run patient often
develop comorbid major type manag medic via oral antidiabet
drug combin diet nutrit approxim type
patient requir extens insulin therapi estim insulin-depend type
 less current pump therapi rest treat
figur insulin-depend diabet ou
svb leerink estim censu idf diabet atla edit cdc nation
long-term potenti market
estim type patient type
patient ou adopt pump therapi insulin pump therapi also known continu
subcutan insulin infus design mimic nondiabet insulin deliveri
pattern slow basal rate throughout day patient-activ bolu deliveri meal time
insulin pump therapi improv glycem control reduc glycem variabl nearli
insulin-depend dietet includ type type patient
current treat insulin pump vast major pump adopt
nearli type patient type patient ou administ
insulin mdi multipl daili inject well almost insulin-depend type
patient therapi involv inject long-act insulin twice daili background
basal dose inject rapid-act insulin meal time
expect penetr ou signific
upsid estim physician pump survey link expect
penetr ramp ultim saw today suggest
point runway adopt diabet market model project modest increment
ramp point point intern leav signific
runway growth forese futur pump therapi ultim becom standard care
cannula put skin everi daysinject need sever time day press button deliv dose meal snack need inject meal snack basal insulin turn reduc sportsani chang basal insulin need done sever hour advancebas insulin constantli deliv need rememb inject background insulin specif time day pump program deliv insulin certain time day even asleep requir increas insulin must inject manual disconnect short period time inject need occasion issu air bubbl advers affect blood glucos level also suffer air bubbl gener less problem tube sometim get caught object door handl tube kept cover tube steeper initi learn curv adjust use care pump less complic learn use maintain insulin pen prosconsprosconsinsulin pumpsmultipl daili inject tandem diabet inc
figur insulin therapi adopt
estim total patient pump therapi
intern market share close
diabet oper becom pump manufactur
market share outsid roch also major player pump market
accu-check spirit pump
figur market share instal base project
figur intern market share instal base project
compani report svb leerink estim
mdt minim insulin pump market share global
minim found insulin therapi compani develop minim insulin
pump revolution insulin deliveri patient could dose pump
provid basal flow bolu need acquir minim
launch first integr cgm/insulin pump system minim paradigm system
septemb launch minim close loop system
consist pump guardian sensor transmitt minim system
deliv basal insulin user select rate importantli system
program automat adjust deliveri basal insulin base cgm sensor valu
suspend insulin deliveri sensor glucos valu fall predict fall
predefin threshold level look forward mdt next-gener hybrid closed-loop
system expect late time-frame
highli differenti patch pump market share ww offer
omnipod system tubeless patch pump worn three day highli
differenti product design market share insulin pump market
intern jnj anima exit market hold share posit
 domest omnipod sale instal base exit base
estim start roll omnipod dash insulin manag
consist dispos patch pump hold unit insulin person
diabet manag touch-screen handheld devic use wirelessli control
pod notabl provid patient pharmaci channel free vs
previous elimin starter cost drive signific ramp adopt
jnj exit pump market benefit pump manufactur
anima instal base come upgrade/switch announc patient transit
program expect captur larger share anima patient
also benefit support pump survey link
physician survey estim jnj anima market share type patient
type patient point share shift point
point remain brand mdi base report new pump
shipment anima switcher meaning sourc upsid
tandem vast major ou adopt anima patient anima complet
market believ bolu new add anima fade
figur anima patient move competitor
roch offer accu-chek combo consist accu-chek spirit insulin pump
accu-check aviva glucos meter two-way bluetooth connect pump
meter accu-chek receiv fda clearanc juli product hasnt gain
much traction market result compani decid exit pump market
howev estim product market share europ basic
size instal base believ market share diabet
industri move toward artifici pancrea view rog bgm pump combo nich
blickenstaff execut chairman mr blickenstaff serv execut chairman
sinc march step ceo mr blickenstaff join tandem
tandem board director mr blickenstaff previous employ chairman chief
execut offic biosit incorpor provid medic diagnost product
acquisit inver medic innov inc june director mediv
inc mdvn biotechnolog compani acquisit
director inc june septemb mr blickenstaff receiv
 polit scienc loyola univers chicago graduat
school busi loyola univers chicago
john sheridan presid ceo john sheridan serv presid chief execut
offic sinc march previous serv execut vice presid chief oper
offic sinc april prior tandem serv rapiscan system inc
provid secur equip system march februari mr sheridan
serv execut vice presid research develop oper volcano
corpor volc medic technolog compani novemb march
may may mr sheridan serv execut vice presid oper
cardionet inc medic technolog compani march may serv
vice presid oper digirad corpor medic imag compani mr sheridan
hold chemistri univers west florida boston
leigh vossel evp cfo ms vossel join tandem august vice-president financ
appoint evp cfo januari prior join tandem ms vossel
serv variou senior financ posit healthcar industri recent vice-president
cfo genoptix inc novarti compani prior held senior financ posit
biosit incorpor play key role develop financi administr
infrastructur intern expans ms vossel certifi public account inact
hold bachelor degre account missouri state univers
susan morrison evp cao appoint chief administr offic septemb
ms morrison serv director corpor servic novemb decemb
director corpor investor relat januari march vice-president
human resourc corpor investor relat april septemb prior
ms morrison held variou posit corpor investor relat biosit
august novemb ms morrison hold public relat
brian hansen evp chief commerci offic brian hansen join tandem evp
chief commerci offic februari year sale leadership
experi clinic diagnost industri prior join tandem mr hansen chief
commerci offic adapt biotechnolog corpor held execut
senior-level posit genoptix novartis-own compani gen-prob acquir
fisher scientif mr hansen receiv school busi san
diego state univers busi administr univers missouri-
dollar million except per share data
total good sold
research develop expens
loss extinguish debt
chang fair valu stock warrant
sg sale
 sale
compani report svb leerink estim
oper expens sale
dollar million
cash equival
equival
prepaid expens
total liabil equiti
compani report svb leerink estim
dollar million
adjust reconcil net loss cash oper activ
depreci amort expens
interest expens relat amort debt discount
provis allow doubt account
provis inventori reserv
chang fair valu common prefer stock warrant
amort premium discount short-term invest
payment kind interest accrual note payabl
chang oper asset liabil
prepaid current asset
net cash use provid oper activ
purchas short-term invest
proce sale matur short-term invest
purchas patent
net cash use provid invest activ
proce public offer net offer cost
proce exercis warrant
proce issuanc common stock
issuanc note payabl net issuanc cost
princip payment note payabl
proce issuanc prefer stock
net cash provid financ activ
effect exchang rate chang cash cash equival
decreas increas cash cash equival
balanc begin period
restrict begin period
cash equival begin period
less restrict end period
cash equival end period
compani report svb leerink estim
ou sale
ou sale
includ ou sale
adjust ebitda
estim
adjust ebitda
estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu division revenu item come visibl alpha
consensu
compani report factset consensu visibl alpha svb leerink estim
slim control iq
previous refer slim
tandem aid system expect integr slim
pump combin dxcm sensor aid technolog
tandem licens typezero hybrid close loop product
sport pump expect half size slim mobil
phone control design peopl seek even greater
discret flexibl use insulin pump sport
also control-iq algorithm rest pump bolu button
pump event peopl lose phone
anticip portion trial util slim integr
typezero incontrol aid algorithm design automat adjust
person insulin base inform receiv sensor
intend use result portion trial pma submiss
-enrol studi complet octob
-a compil data plan submit approv juli
track file modular pma submiss fda
plan submit regulatori file fda control-iq
peopl year old juli plan submit separ regulatori
file pediatr data studi data avail
